cenegerminbkbj

Cenegermin-bkbj is the international nonproprietary name for a recombinant human nerve growth factor used as an ophthalmic therapy. It is a protein biologic designed to substitute the activity of endogenous nerve growth factor in the cornea. Cenegermin-bkbj is approved for the treatment of neurotrophic keratitis and is marketed under the brand name Oxervate in many jurisdictions.

Neurotrophic keratitis is a degenerative corneal disease caused by reduced corneal innervation and impaired healing. Cenegermin-bkbj acts by binding to nerve growth factor receptors on corneal cells, promoting neuronal survival and axonal regrowth, which supports epithelial healing and restoration of corneal integrity. This mechanism targets the underlying nerve deficiency rather than merely treating symptoms.

Administration consists of a sterile 0.002% ophthalmic solution given as drops in affected eyes six times daily at two-hour intervals for eight weeks. The product requires refrigeration and careful handling. Patients should avoid wearing contact lenses during treatment unless advised; follow-up examinations are typical to assess healing and detect adverse reactions.

Regulatory status: cenegermin-bkbj has been approved in several regions for NK and is subject to standard biologic-drug safety monitoring. Common adverse effects reported in trials include ocular irritation, conjunctival hyperemia, tearing, and mild eye pain. As with other biologics, efficacy and safety considerations may vary with patient age, comorbidity, and severity of corneal disease.